Trial Profile
A Phase 2/3, Randomized, Double-Blind, Placebo Controlled, Multicenter Study of Efficacy and Safety of Adalimumab in Japanese Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 27 Oct 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Abbott Japan
- 26 Feb 2010 Results have been published in the Journal of Dermatology Volume 37 Issue 4, Pages 299 - 310, Published Online: 26 Feb 2010. Actual end date added.
- 26 Feb 2010 New trial record.